Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.09
ACOR's Cash to Debt is ranked lower than
77% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ACOR: 1.09 )
Ranked among companies with meaningful Cash to Debt only.
ACOR' s Cash to Debt Range Over the Past 10 Years
Min: 1.03  Med: 31.09 Max: N/A
Current: 1.09
Equity to Asset 0.52
ACOR's Equity to Asset is ranked lower than
67% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACOR: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
ACOR' s Equity to Asset Range Over the Past 10 Years
Min: -3.98  Med: 0.52 Max: 0.75
Current: 0.52
-3.98
0.75
Interest Coverage 1.92
ACOR's Interest Coverage is ranked lower than
95% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACOR: 1.92 )
Ranked among companies with meaningful Interest Coverage only.
ACOR' s Interest Coverage Range Over the Past 10 Years
Min: 3.92  Med: 11.72 Max: 13.99
Current: 1.92
3.92
13.99
F-Score: 5
Z-Score: 2.44
M-Score: -0.66
WACC vs ROIC
12.81%
1.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.52
ACOR's Operating margin (%) is ranked higher than
74% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ACOR: 6.52 )
Ranked among companies with meaningful Operating margin (%) only.
ACOR' s Operating margin (%) Range Over the Past 10 Years
Min: -668.67  Med: -45.11 Max: 12
Current: 6.52
-668.67
12
Net-margin (%) 0.46
ACOR's Net-margin (%) is ranked higher than
70% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ACOR: 0.46 )
Ranked among companies with meaningful Net-margin (%) only.
ACOR' s Net-margin (%) Range Over the Past 10 Years
Min: -690.44  Med: -46.99 Max: 50.67
Current: 0.46
-690.44
50.67
ROE (%) 0.40
ACOR's ROE (%) is ranked higher than
76% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ACOR: 0.40 )
Ranked among companies with meaningful ROE (%) only.
ACOR' s ROE (%) Range Over the Past 10 Years
Min: -92.5  Med: -2.28 Max: 52.43
Current: 0.4
-92.5
52.43
ROA (%) 0.20
ACOR's ROA (%) is ranked higher than
77% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ACOR: 0.20 )
Ranked among companies with meaningful ROA (%) only.
ACOR' s ROA (%) Range Over the Past 10 Years
Min: -109.5  Med: -15.75 Max: 32.8
Current: 0.2
-109.5
32.8
ROC (Joel Greenblatt) (%) 70.65
ACOR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ACOR: 70.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACOR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4354.61  Med: -954.97 Max: 1008.02
Current: 70.65
-4354.61
1008.02
Revenue Growth (3Y)(%) 9.00
ACOR's Revenue Growth (3Y)(%) is ranked higher than
63% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ACOR: 9.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACOR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.8  Med: 9.00 Max: 73.6
Current: 9
-61.8
73.6
EBITDA Growth (3Y)(%) 2.60
ACOR's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ACOR: 2.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACOR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -80.8  Med: -67.75 Max: 20.5
Current: 2.6
-80.8
20.5
EPS Growth (3Y)(%) -18.40
ACOR's EPS Growth (3Y)(%) is ranked lower than
67% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ACOR: -18.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACOR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -84  Med: -57.50 Max: -12.3
Current: -18.4
-84
-12.3
» ACOR's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ACOR Guru Trades in Q1 2015

Paul Tudor Jones 14,200 sh (New)
John Hussman 210,000 sh (New)
Jim Simons 319,000 sh (+489.65%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
» More
Q2 2015

ACOR Guru Trades in Q2 2015

Paul Tudor Jones Sold Out
Jim Simons 284,300 sh (-10.88%)
John Hussman 136,000 sh (-35.24%)
» More
Q3 2015

ACOR Guru Trades in Q3 2015

Steven Cohen 1,082,719 sh (New)
Jim Simons Sold Out
John Hussman 55,000 sh (-59.56%)
» More
Q4 2015

ACOR Guru Trades in Q4 2015

John Hussman 100,000 sh (+81.82%)
» More
» Details

Insider Trades

Latest Guru Trades with ACOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 766.70
ACOR's P/E(ttm) is ranked lower than
98% of the 374 Companies
in the Global Biotechnology industry.

( Industry Median: 35.73 vs. ACOR: 766.70 )
Ranked among companies with meaningful P/E(ttm) only.
ACOR' s P/E(ttm) Range Over the Past 10 Years
Min: 6.35  Med: 63.49 Max: 894.79
Current: 766.7
6.35
894.79
Forward P/E 28.90
ACOR's Forward P/E is ranked lower than
82% of the 347 Companies
in the Global Biotechnology industry.

( Industry Median: 16.47 vs. ACOR: 28.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 736.00
ACOR's PE(NRI) is ranked lower than
97% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 33.50 vs. ACOR: 736.00 )
Ranked among companies with meaningful PE(NRI) only.
ACOR' s PE(NRI) Range Over the Past 10 Years
Min: 6.35  Med: 63.16 Max: 859
Current: 736
6.35
859
P/B 2.74
ACOR's P/B is ranked lower than
51% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. ACOR: 2.74 )
Ranked among companies with meaningful P/B only.
ACOR' s P/B Range Over the Past 10 Years
Min: 2.08  Med: 4.59 Max: 44.88
Current: 2.74
2.08
44.88
P/S 3.33
ACOR's P/S is ranked higher than
79% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. ACOR: 3.33 )
Ranked among companies with meaningful P/S only.
ACOR' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 4.40 Max: 24.53
Current: 3.33
0.12
24.53
PFCF 80.01
ACOR's PFCF is ranked lower than
82% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 27.59 vs. ACOR: 80.01 )
Ranked among companies with meaningful PFCF only.
ACOR' s PFCF Range Over the Past 10 Years
Min: 10.97  Med: 30.22 Max: 130.85
Current: 80.01
10.97
130.85
POCF 54.10
ACOR's POCF is ranked lower than
77% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 25.75 vs. ACOR: 54.10 )
Ranked among companies with meaningful POCF only.
ACOR' s POCF Range Over the Past 10 Years
Min: 9.61  Med: 26.95 Max: 66.66
Current: 54.1
9.61
66.66
EV-to-EBIT 48.31
ACOR's EV-to-EBIT is ranked lower than
76% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.26 vs. ACOR: 48.31 )
Ranked among companies with meaningful EV-to-EBIT only.
ACOR' s EV-to-EBIT Range Over the Past 10 Years
Min: -106.6  Med: -1.00 Max: 89.8
Current: 48.31
-106.6
89.8
EV-to-EBITDA 33.53
ACOR's EV-to-EBITDA is ranked lower than
74% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 17.11 vs. ACOR: 33.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACOR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -214.7  Med: -1.00 Max: 66.6
Current: 33.53
-214.7
66.6
Current Ratio 4.61
ACOR's Current Ratio is ranked higher than
50% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ACOR: 4.61 )
Ranked among companies with meaningful Current Ratio only.
ACOR' s Current Ratio Range Over the Past 10 Years
Min: 0.59  Med: 3.72 Max: 8.36
Current: 4.61
0.59
8.36
Quick Ratio 4.10
ACOR's Quick Ratio is ranked higher than
50% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ACOR: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
ACOR' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.40 Max: 8.09
Current: 4.1
0.42
8.09
Days Inventory 156.30
ACOR's Days Inventory is ranked lower than
60% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ACOR: 156.30 )
Ranked among companies with meaningful Days Inventory only.
ACOR' s Days Inventory Range Over the Past 10 Years
Min: 120  Med: 219.02 Max: 332.51
Current: 156.3
120
332.51
Days Sales Outstanding 24.17
ACOR's Days Sales Outstanding is ranked higher than
81% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ACOR: 24.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACOR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.51  Med: 36.79 Max: 57.6
Current: 24.17
28.51
57.6
Days Payable 55.86
ACOR's Days Payable is ranked lower than
52% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ACOR: 55.86 )
Ranked among companies with meaningful Days Payable only.
ACOR' s Days Payable Range Over the Past 10 Years
Min: 80.37  Med: 170.50 Max: 383.28
Current: 55.86
80.37
383.28

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.76
ACOR's Price/Projected FCF is ranked higher than
72% of the 296 Companies
in the Global Biotechnology industry.

( Industry Median: 3.14 vs. ACOR: 1.76 )
Ranked among companies with meaningful Price/Projected FCF only.
ACOR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.32  Med: 2.82 Max: 22.28
Current: 1.76
1.32
22.28
Price/Median PS Value 0.72
ACOR's Price/Median PS Value is ranked higher than
63% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. ACOR: 0.72 )
Ranked among companies with meaningful Price/Median PS Value only.
ACOR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.99 Max: 5
Current: 0.72
0.04
5
Earnings Yield (Greenblatt) (%) 2.11
ACOR's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ACOR: 2.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACOR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 2.70 Max: 7.7
Current: 2.11
1.1
7.7

More Statistics

Revenue(Mil) $480
EPS $ 0.05
Beta1.57
Short Percentage of Float21.50%
52-Week Range $25.50 - 43.63
Shares Outstanding(Mil)43.16

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 491 510 549 736
EPS($) -0.47 -1.03 -1.16 1.94
EPS without NRI($) -0.47 -1.03 -1.16 1.94

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CDG.Germany,
Acorda Therapeutics Inc was incorporated on March 17, 1995 as a Delaware corporation. It is a biopharmaceutical company, engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec. The Company also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. The Company is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for "Fampyra" and "Kampyra" and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks "Zanaflex" and "Zanaflex Capsules" and "Qutenza" in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
» More Articles for ACOR

Headlines

Articles On GuruFocus.com
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Acorda Therapeutics Inc. Reports Operating Results (10-K) Mar 01 2011 
Steve Cohen Buys ACOR, DPZ, GXDX, NDN, and OREX Feb 07 2011 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 15,000 Shares Dec 03 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 10,905 Shares Dec 03 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 55,000 Shares Aug 09 2010 
Acorda Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Acorda Therapeutics Inc. (ACOR) CFO David Lawrence sells 12,000 Shares Mar 12 2010 
Acorda Therapeutics Inc. (ACOR) President and CEO Ron Cohen sells 38,000 Shares Mar 10 2010 

More From Other Websites
Why Acorda Therapeutics (ACOR) Might Surprise This Earnings Season Feb 10 2016
3 Biotech Stocks to Turn the Tide This Earnings Season Feb 08 2016
Acorda Therapeutics to Present at Two Investor Conferences in February Feb 04 2016
Should Acorda Therapeutics (ACOR) Be On Your Radar Now? Feb 02 2016
Acorda Announces a Recommended Cash Tender Offer for All Shares, ADSs and Other Equity Instruments... Jan 28 2016
Acorda to Host Conference Call to Discuss Fourth Quarter and Year End 2015 Results on February 11,... Jan 28 2016
Allergan's Botox Gains FDA Nod for Lower Limb Spasticity Jan 26 2016
Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : January 26, 2016 Jan 26 2016
Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : January 26, 2016 Jan 26 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Unregistered Sale of Equity Securities Jan 25 2016
Acorda Therapeutics Confirms It Entered Into A Patent Litigation Settlement Deal With Par Pharma Jan 21 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events Jan 20 2016
Biotie Therapies Soars on $363M Buyout Deal with Acorda Jan 20 2016
Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie Jan 20 2016
Acorda Biotie Tender Announcement (Finland Press Release) Jan 20 2016
ACORDA THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... Jan 19 2016
Acorda Therapeutics To Acquire Biotie Therapies To Boost Its Parkinson's Disease Therapeutic... Jan 19 2016
Acorda Acquires Parkinson's Drug Through Biotie Buyout Jan 19 2016
U.S. firm Acorda to buy Finland's Biotie for $363 million Jan 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK